Los Angeles, CA (PRWEB) January 23, 2012
EveryMD (http://www.everymd.com) has announced the immediate limited-time availability of licenses to EveryMD’s U.S. Patent No. 7,644,122 entitled “Method, Apparatus and Business System for Online Communications with Online and Offline Recipients” which covers the creation and use of Facebook member pages.
EveryMD’s patent was issued on Jan. 5, 2010 based on a patent application first filed in November 1999. The patent covers technology originally developed for EveryMD’s website at http://www.everymd.com, which has been in continuous operation since 2001.
Under U.S. patent laws, a process patent such as EveryMD’s covers both the patented process itself and the commercial use of the products produced by that process. Usually a commercial user of a patented process takes responsibility for obtaining the rights to use the patented process so as to insulate its customers from patent infringement liability. EveryMD had offered Facebook the opportunity to obtain rights under EveryMD’s patent to protect Facebook users, but Facebook has ignored the offer and chosen instead to hire teams of high-priced lawyers to attempt to steamroll EveryMD in the courts. Facebook’s actions have left EveryMD no choice but to seek enforcement of its rights directly with Facebook’s commercial customers.
To remedy the economic and legal risk to commercial Facebook users resulting from Facebook’s actions, EveryMD is launching a special patent licensing program that will allow commercial Facebook users to obtain limited, non-exclusive, non-transferable licenses to EveryMD’s “Facebook” patent for a one-time royalty payment of $500 per business account. This special low price will be available for a limited time only.
Facebook business account users who wish to take advantage of this low cost commercial licensing opportunity, thereby avoiding potential future patent infringement litigation, can find more information at EveryMD’s website at http://www.everymd.com under the “Licensing” tab.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/1/prweb9123753.htm